Dr Reddy's completes Rs 1,569.41 crore share buyback

In February this year, the company's board had approved a proposal to buyback shares

Dr Reddy's Labs
Press Trust of India New Delhi
Last Updated : Jun 28 2016 | 4:14 PM IST
Drug major Dr Reddy's Laboratories today said it has bought back nearly 51 lakh shares for Rs 1,569.41 crore as part of a 'share buyback' offer launched earlier this year.

The company has bought back 50,77,504 equity shares at an average price of Rs 3,090.92 per share. The company has thus deployed Rs 1,569.41 crore against the maximum buyback size, Dr Reddy's Laboratories said in a regulatory filing.

"Consequently, the company announces the closure of its buyback," it added.

In February this year, the company's board had approved a proposal to buyback shares, subject to the approval of shareholders, for an aggregate of amount not exceeding Rs 1,569.4 crore at a price not more than Rs 3,500 per share under the open market route.

The Hyderabad-based company's shareholders approved the buyback offer on April 1.

The share buyback offer comes at a time when the drug maker is facing heat from the US Food and Drug Administration (USFDA) for manufacturing norm violations at three of its plants.

In November last year, the company received a warning letter from the USFDA for several violations with regard to current good manufacturing practices in API manufacturing facilities at Srikakulam in Andhra Pradesh and Miryalaguda in Telangana, as well as in oncology formulation manufacturing facility at Duvvada, Visakhapatnam in Andhra Pradesh.

Shares of the company were trading at Rs 3,266.80, up 0.81%, on BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 28 2016 | 3:13 PM IST

Next Story